Newswise — Toronto, ON, Canada, April 29, 2014 – Quality of life (QOL) is rarely reported in surgical publications, yet it can be an important metric that can be of use to physicians and patients when making treatment decisions. Prior studies of average-risk patients undergoing lobectomy suggested that low baseline QOL scores predict worse survival in patients undergoing non-small cell lung cancer surgery. The results of a multi-center, longitudinal study of high-risk lung cancer patients who underwent sublobar resection counters this idea, finding that poor baseline global QOL scores did not predict for worse overall survival or recurrence-free survival or greater risk of adverse events. Bryan F. Meyers, MD, is presenting the results of this research on behalf of the Alliance for Clinical Trials in Oncology at the 94th AATS Annual Meeting in Toronto, ON, Canada on April 29, 2014.
“The longitudinal quality of life information now available from this study can be factored into clinical decision-making for high-risk lung cancer patients facing surgery,” comments lead investigator Hiran C. Fernando, MD, Chief of the Division of Thoracic Surgery, Boston Medical Center. The results of this study suggest that having poor global quality of life initially should not exclude patients as surgical candidates based on unfounded expectations of poor survival.
The results were generated as part of the Alliance Study (ACOSOG Z4032), in which high-risk operable patients with biopsy proven stage I lung cancers of 3 cm or less were randomized to sublobar resection or sublobar resection with brachytherapy. Two hundred and twelve patients were eligible for the study. Global QOL using the SF-36 (physical [PCS] and mental [MCS] components) were measured at baseline, 3, 12, and 24 months after surgery, as was difficult or labored breathing (dyspnea) using the University of California San Diego (UCSD) scale. The median length of follow-up on alive patients was more than 4 years. Because no differences were found between surgical groups for PCS, MCS, or UCSD measures at any time point, the two surgical groups were combined for data analysis.
In these lung cancer patients, who were generally 70 years of age or older and had poor initial lung function, baseline PCS and MCS scores (that were lower than the U.S. normal values) did not predict poor survival. What did impact overall survival was having breathing problems as measured by low UCSD scores at baseline or experiencing a significant decline in breathing function at 12 months.
The study also found that global QOL and dyspnea did not deteriorate significantly after sublobar resection. Those who experienced a significant decline in PCS, MCS, or UCSD at 3 months showed no difference in recurrence-free survival compared to those who showed no such changes.
There were some indications that the surgical technique affected QOL, with better results associated with video-assisted thoracic surgery rather than thoracotomy, and wedge resection rather than segmentectomy.
# # #
NOTES FOR EDITORS“Analysis of longitudinal quality of life data in high-risk operable patients with lung cancer: Results from ACOSOG Z4032 (Alliance) a multicenter randomized trial,” by Hiran C. Fernando, MD, Rodney J. Landreneau, MD, Sumithra J. Mandrekar, PhD, Francis C. Nichols, MD, Thomas A. DiPetrillo, MD, Bryan F. Meyers, MD, Dwight E. Heron, MD, Shauna Hillman, MS, David R. Jones, MD, Sandra L. Starnes, MD, Angelina D. Tan, BS, Benedict D. T. Daly, MD, and Joe B. Putnam, MD, for the Alliance for Clinical Trials in Oncology. Presentation at the 94th AATS Annual Meeting April 26-30, 2014, Toronto, ON, Canada, by Dr. Bryan F. Meyers, during the Plenary Scientific Session on April 29, 11:20 AM ET. http://aats.org/annualmeeting
For more information contact Nicole Baritot, Managing Editor, AATS Scientific Publications, at +1 978-299-4520 or firstname.lastname@example.org. Journalists wishing to interview Dr. Fernando may contact him via Gina DiGravio at +1 617-638-8480 or Gina.Digravio@bmc.org. The presentation abstract is located at http://www.aats.org/annualmeeting/Program-Books/2014/41.cgi.
ABOUT THE AUTHORSHiran C. Fernando, MD, Boston Medical Center, Boston MA Rodney J. Landreneau, MD, University of Pittsburgh, Pittsburgh, PA Sumithra J. Mandrekar, PhD, Alliance Statistics and Data Center, Mayo Clinic, Rochester, MNFrancis C. Nichols, MD, Mayo Clinic, Rochester, MN Thomas A. DiPetrillo, MD, Rhode Island Hospital, Providence RIBryan F. Meyers, MD, Washington University of St Louis, St. Louis MODwight E. Heron, MD, University of Pittsburgh, Pittsburgh, PAShauna Hillman, MS, Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN David R. Jones, MD, University of Virginia, Charlottesville VASandra L. Starnes, MD, University of Cincinnati, Cincinnati OH Angelina D. Tan, BS, Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN Benedict D. T. Daly, MD, University of Pittsburgh, Pittsburgh, PA Joe B. Putnam, MD, Vanderbilt University Medical Center, Nashville TN
ABOUT THE AMERICAN ASSOCIATION FOR THORACIC SURGERY (AATS)The American Association for Thoracic Surgery (AATS) is an international organization of over 1,300 of the world’s foremost thoracic and cardiothoracic surgeons, representing 35 countries. AATS encourages and stimulates education and investigation into the areas of intrathoracic physiology, pathology and therapy. Founded in 1917 by a respected group of the last century’s earliest pioneers in the field of thoracic surgery, the AATS’ original mission was to “foster the evolution of an interest in surgery of the Thorax.”
One hundred years later, the AATS continues to be the premiere association among cardiothoracic surgeons. The purpose of the Association is the continual enhancement of the ability of cardiothoracic surgeons to provide the highest level of quality patient care. To this end, the AATS encourages, promotes, and stimulates the scientific investigation and study of cardiothoracic surgery. Visit www.aats.org.